Female patients of childbearing potential must test negative for pregnancy prior to enrolling in the trial. Exclusion Criteria Heat Biologics, Inc. Protocol HS410-101 HS410-101 SAP version 1.0 Page 13 of 25 Patients that meet any of the following exclusion criteria are not eligible to be enrolled into the study: 1. Known human immunodeficiency virus (HIV) infection or other immunodeficiency disorders, either primary or acquired 2. Infections or concurrent illness, requiring active therapy 3. Any condition requiring active steroid or other immunosuppressive therapy 4. Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome 5. Prior prostatic pelvic radiation within the past 12 months 6. Known history of clinically significant cardiac impairment, congestive heart failure > New York Heart Association (NYHA) cardiac disease classification Class II, unstable angina, or myocardial infarction during the previous three months 7. Known current alcohol or chemical abuse, or mental or psychiatric condition precluding compliance with the protocol 8. Pregnant or nursing 9. Known allergy to soy, egg, or peanut products 10. Receiving another investigational agent (30 day wash-out required prior to first dose) 11. Neo-adjuvant therapy prior to the baseline staging procedure for the current occurrence of non- muscle invasive bladder cancer 12. Prior treatment with a cancer vaccine for this indication 13. Prior vaccination with BCG for tuberculosis disease 14. Prior splenectomy 3.4 Randomisation and Blinding Patients will be randomized to Arms 1-3 centrally using a randomized block design, stratified for risk of recurrence (strata: high vs. intermediate risk) and CIS (strata: yes vs.